Literature DB >> 32164125

[Trend analysis on the disease burden related to cirrhosis and other chronic liver diseases caused by hepatitis B, in China, from 1990 to 2016].

L Zhang1, Z F Fan1, D W Liu1, M G Zhou2, Z Q Wang2, M Li1.   

Abstract

Objective: The aim of this study was to analyze the disease burden of cirrhosis and other chronic liver diseases caused by hepatitis B in China, from 1990 to 2016, and to provide evidence for the development of related strategies.
Methods: Data were collected from the results of the Global Burden of Disease Study 2016 (GBD2016). We analyzed the current epidemiological patterns by calculating the prevalence, mortality, and disability adjusted life year (DALY) of cirrhosis and other chronic liver diseases, caused by hepatitis B during 1990 and 2016 in China.
Results: Compared with data from 1990, the number of patients and deaths with cirrhosis and other chronic liver diseases caused by hepatitis B in 2016 increased by 79.6% and 2.4%, respectively. The prevalence increased by 49.2%, higher (50.3%) in males than that (42.3%) in females. Compared with other age groups, the increase (33.2%) of prevalence appeared the fastest, in the 15-49 age group. In males, the number of deaths and DALYs increased by 13.6% and 2.2%, respectively. In 2016, the five top provinces on age-standardized DALY rates, appeared as Qinghai (314.6 per 100 000), Guizhou (303.1 per 100 000), Yunnan (262.4 per 100 000), Guangxi Zhuang Autonomous Region (239.6 per 100 000) and Taiwan (227.2 per 100 000). Conclusions: From 1990 to 2016, the prevalence rates of hepatitis B related cirrhosis and other chronic liver diseases showed an upward trend, particularly in males and in people aged 15 to 49 years old, in China. However, the disease burden of different provinces was unevenly distributed. Based on our findings, we suggested that strategies that related to prevention and management of hepatitis B caused cirrhosis and other chronic liver diseases should be paid more attention to.

Entities:  

Keywords:  Burden of disease; Cirrhosis; Disability adjusted life year; Hepatitis B

Mesh:

Year:  2020        PMID: 32164125     DOI: 10.3760/cma.j.issn.0254-6450.2020.02.007

Source DB:  PubMed          Journal:  Zhonghua Liu Xing Bing Xue Za Zhi        ISSN: 0254-6450


  3 in total

1.  Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China.

Authors:  Runqin Li; Xiao Lin; Jing-Yue Wang; Xiaomo Wang; Junfeng Lu; Yali Liu; Zhenhuan Cao; Shan Ren; Lina Ma; Yi Jin; Sujun Zheng; Zhongjie Hu; Li Wang; Xinyue Chen
Journal:  Ann Transl Med       Date:  2021-09

2.  Analyzing the Spatiotemporal Distribution and Characteristics of Liver Cirrhosis in Hospitalized Patients in Wuwei, Gansu Province During 1995-2016: A Long-Term Retrospective Study.

Authors:  Yang Zhang; Ting Fu; Xiao-Jie Yuan; Yan-Cheng Ye; Zhi-Wen Guo; Kun Liu; Zhao-Hua Ji; Zhong-Jun Shao
Journal:  Front Physiol       Date:  2022-03-22       Impact factor: 4.566

3.  Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China.

Authors:  Xin Zeng; Zhi-Wen Shi; Jia-Jun Yu; Li-Fen Wang; Yuan-Yuan Luo; Si-Min Jin; Li-Yuan Zhang; Wei Tan; Pei-Mei Shi; Hong Yu; Chun-Qing Zhang; Wei-Fen Xie
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-09-14       Impact factor: 12.910

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.